The obesity paradox in cancer-moving beyond BMI

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 1, 2017, Pages 13-16

  Shachar, Shlomit Strulov ^a,b   Williams, Grant R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Division of Oncology   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; BODY COMPOSITION; BODY MASS; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; FAT MASS; HUMAN; INTRAPERITONEAL FAT; LEAN BODY WEIGHT; MALIGNANT NEOPLASM; MORTALITY RISK; MUSCLE MASS; MUSCLE TISSUE; OBESITY; OBESITY PARADOX; PRIORITY JOURNAL; RACE DIFFERENCE; SUBCUTANEOUS FAT; WEIGHT CHANGE; WEIGHT REDUCTION; ADULT; AGED; BODY WEIGHT; COMORBIDITY; COMPARATIVE STUDY; FEMALE; MALE; MIDDLE AGED; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL ANALYSIS;

ADULT; AGED; BODY COMPOSITION; BODY MASS INDEX; BODY WEIGHT; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OBESITY; REFERENCE VALUES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 85009069318     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0439     Document Type: Article

References (51)

1. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5.24 million UK adults. Lancet 2014;384:755-65.
2. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-Analysis. JAMA 2013;309:71-82.
3. Tobias DK, Pan A, Jackson CL, O'Reilly EJ, Ding EL, Willett WC, et al. Bodymass index and mortality among adults with incident type 2 diabetes. N Engl J Med 2014;370:233-44.
4. Andersen KK, Olsen TS. The obesity paradox in stroke: lower mortality and lower risk of readmission for recurrent stroke in obese stroke patients. Int J Stroke 2013 Mar 12. [Epub ahead of print].
5. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005;165:55-61.
6. Dixon JB, Egger GJ. A narrow view of optimal weight for health generates the obesity paradox. Am J Clin Nutr 2014;99:969-70.
7. Cespedes Feliciano EM, Kroenke CH, Bradshaw PT, Chen WY, Prado CM, Weltzien EK, et al. Postdiagnosis weight change and survival following a diagnosis of early-stage breast cancer. Cancer Epidemiol Biomarkers Prev 2017;26:44-50.
8. Meyerhardt JA, Kroenke CH, Prado CM, Kwan ML, Castillo A, Weltzien E, et al. Association of weight change after colorectal cancer diagnosis and outcomes in the Kaiser Permanente Northern California population. Cancer Epidemiol Biomarkers Prev 2017;26:30-7.
9. Greenlee H, Unger JM, LeBlanc M, Ramsey S, Hershman DL. Association between body mass index (BMI) and cancer survival in a pooled analysis of 22 clinical trials. Cancer Epidemiol Biomarkers Prev 2017;26:21-9.
10. Colantonio LD, Burrone MS. Factors involved in the paradox of reverse epidemiology. Clin Nutr 2014;33:729.
11. Banack HR, Kaufman JS. From bad to worse: collider stratification amplifies confounding bias in the "obesity paradox". Eur J Epidemiol 2015;30:1111-4.
12. Sperrin M, Candlish J, Badrick E, Renehan A, Buchan I. Collider bias is only a partial explanation for the obesity paradox. Epidemiology 2016;27: 525-30.
13. Broughman JR, Williams GR, Deal AM, Yu H, Nyrop KA, Alston SM, et al. Prevalence of sarcopenia in older patients with colorectal cancer. J Geriatr Oncol 2015;6:442-5.
14. Gioulbasanis I, Baracos VE, Giannousi Z, Xyrafas A, Martin L, Georgoulias V, et al. Baseline nutritional evaluation in metastatic lung cancer patients: mini nutritional assessment versus weight loss history. Ann Oncol 2011;22:835-41.
15. Klesges RC, Meyers AW, Klesges LM, La Vasque ME. Smoking, body weight, and their effects on smoking behavior: A comprehensive review of the literature. Psychol Bull 1989;106:204-30.
16. Newman AB, Yanez D, Harris T, Duxbury A, Enright PL, Fried LP. Weight change in old age and its association with mortality. J Am Geriatr Soc 2001;49:1309-18.
17. Wallace JI, Schwartz RS. Involuntary weight loss in elderly outpatients: recognition, etiologies, and treatment. Clin Geriatr Med 1997;13:717-35.
18. Kritchevsky SB, Wilcosky TC, Morris DL, Truong KN, Tyroler HA. Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res 1991;51:3198-203.
19. Petruzzelli M, Wagner EF.Mechanisms ofmetabolic dysfunction in cancerassociated cachexia. Genes Dev 2016;30:489-501.
20. Twig G, Yaniv G, Levine H, Leiba A, Goldberger N, Derazne E, et al. Bodymass index in 2.3 million adolescents and cardiovascular death in adulthood. N Engl J Med 2016;374:2430-40.
21. Shah AD, Kandula NR, Lin F, Allison MA, Carr J, Herrington D, et al. Less favorable body composition and adipokines in South Asians compared with other US ethnic groups: results from the MASALA and MESA studies. Int J Obes 2016;40:639-45.
22. Cruz-Jentoft AJ, Landi F, Schneider SM, Zuniga C, Arai H, Boirie Y, et al. Prevalence of and interventions for sarcopenia in ageing adults: A systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014;43:748-59.
23. Cruz-Jentoft AJ, Landi F, Topinkova E, Michel JP. Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin NutrMetab Care 2010;13:1-7.
24. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, CederholmT, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on Sarcopenia in older people. Age Ageing 2010;39:412-23.
25. Habicht JP. Somecharacteristics of indicators of nutritional status for use in screening and surveillance. Am J Clin Nutr 1980;33:531-5.
26. Kazemi-Bajestani SM, Mazurak VC, Baracos V. Computed tomographydefined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol 2016;54:2-10.
27. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-Analysis and systematic review. Eur J Cancer 2016;57:58-67.
28. Zhuang CL, Huang DD, Pang WY, Zhou CJ, Wang SL, Lou N, et al. Sarcopenia is an independent predictor of severe postoperative complications and long-Term survival after radical gastrectomy for gastric cancer: Analysis from a large-scale cohort. Medicine 2016;95:e3164.
29. Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 2014;32:735-44.
30. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 2011;67: 93-101.
31. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15:2920-6.
32. Joseph N, Clark RM, Dizon DS, Lee MS, Goodman A, Boruta D Jr, et al. Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Gynecol Oncol 2015;137:401-5.
33. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, nodepositive breast carcinoma. N Engl J Med 1994;330:1253-9.
34. Malietzis G, Johns N, Al-Hassi HO, Knight SC, Kennedy RH, Fearon KC, et al. Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer. Ann Surg 2016;263:320-5.
35. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, et al. Association of leisure-Time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern Med 2016;176:816-25.
36. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA 2005;293: 2479-86.
37. Engel F, Hartel S, Wagner MO, Strahler J, Bos K, Sperlich B. Hormonal, metabolic, and cardiorespiratory responses of young and adult athletes to a single session of high-intensity cycle exercise. Pediatr Exerc Sci 2014;26: 485-94.
38. Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer. 2015;137:262-6.
39. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19.
40. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
41. Sjøblom B, Grønberg BH, Wentzel-Larsen T, Baracos VE, Hjermstad MJ, Aass N, et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clin Nutr 2016 Apr 1. [Epub ahead of print].
42. Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, den Braver NR, Berkhof J, Langius JA, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol 2016;34:1339-44.
43. Niraula S, Ocana A, Ennis M, Goodwin PJ. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: Ametaanalysis. Breast Cancer Res Treat 2012;134:769-81.
44. Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J, et al. General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1871-7.
45. Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML. Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-Analysis. J Natl Cancer Inst 2015;107;djv275.
46. Villasenor A, Ballard-Barbash R, Baumgartner K, Baumgartner R, Bernstein L, McTiernan A, et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: The HEAL Study. J Cancer Surviv 2012;6:398-406.
47. Antoun S, Bayar A, Ileana E, Laplanche A, Fizazi K, di Palma M, et al. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer 2015;51:2570-7.
48. Ballian N, Lubner MG, Munoz A, Harms BA, Heise CP, Foley EF, et al. Visceral obesity is associated with outcomes of total mesorectal excision for rectal adenocarcinoma. J Surg Oncol 2012;105:365-70.
49. Balentine CJ, Enriquez J, Fisher W, Hodges S, Bansal V, Sansgiry S, et al. Intra-Abdominal fat predicts survival in pancreatic cancer. J Gastrointest Surg 2010;14:1832-7.
50. Ladoire S, Bonnetain F, Gauthier M, Zanetta S, Petit JM, Guiu S, et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist 2011;16:71-81.
51. Tartari RF, Ulbrich-Kulczynski JM, Filho AF. Measurement of mid-Arm muscle circumference and prognosis in stage IV non-small cell lung cancer patients. Oncol Lett 2013;5:1063-7.